Hsin Tse
Executive Director and VP @ Sino Biopharmaceutical
Hsin Tse is an executive director and a vice president at Sino Biopharmaceutical.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Hsin Tse invests in
Stages Hsin Tse invests in
Countries Hsin Tse invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biopharma 2 (100%)
- Biotechnology 2 (100%)
- Health Care 1 (50%)
Stage
- Series D 1 (50%)
- Venture - Series Unknown 1 (50%)
Country
- China 1 (50%)
- Singapore 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Evive Biotech
|
Evive Biotech develops biological therapies for oncology and inflammatory disorders. The company uses proprietary technology platforms to advance drug candidates. It also manages drug development, regulatory compliance, and commercial-scale manufacturing for biologics. | $70M / Venture - Series Unknown / Jun 02, 2022 | |
Akeso Biopharma
|
The company has built a global level of bio-pharmaceutical research and development and industrialization platform; established for cancer, autoimmune diseases, inflammation and cardiovascular disease of the rich product line. The scale of the company's platform, hardware and software facilities, the number of new drug product lines, R &D team in the country are the same industry-leading level. Kang Fang biological has been with the international and domestic listed pharmaceutical companies to establish a cooperative relationship, the joint development of innovative antibodies to new drugs, is a strategic cooperation in the form of development of new drugs in the forerunner. | $150M / Series D / Nov 04, 2019 |
Co-Investors
About Sino Biopharmaceutical
Sino Biopharmaceutical engages in pharmaceutical products which covers an array of R&D platforms, a line-up of intelligent production and a strong sales system. The Group's products have gained a competitive foothold in various therapeutic categories with promising potentials, comprising a variety of biopharmaceutical and chemicalmedicines for treating tumours, liver diseases, cardio-cerebral diseases, analgesia, respiratory system diseases and orthopedicdiseases.
Sino Biopharmaceutical Contacts
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Hsin Tse invest in?
Hsin Tse invests primarily in Biopharma, Biotechnology and Health Care startups, most often at Series D and Venture - Series Unknown stage. Most of the 2 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Hsin Tse?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Hsin Tse last invest?
The most recent investment recorded for Hsin Tse closed in Jun 2022. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
